Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) insider Mayukh Sukhatme sold 284,707 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares in the company, valued at approximately $675,364,288.75. The trade was a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Mayukh Sukhatme also recently made the following trade(s):
- On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total transaction of $8,810,302.71.
- On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total transaction of $5,029,879.66.
Roivant Sciences Price Performance
Shares of NASDAQ ROIV opened at $37.40 on Thursday. The stock has a market cap of $27.01 billion, a PE ratio of -70.57 and a beta of 1.12. Roivant Sciences Ltd. has a 1 year low of $11.54 and a 1 year high of $37.97. The firm has a fifty day moving average price of $34.34 and a 200-day moving average price of $30.28.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ROIV. Bank of America reaffirmed a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Citigroup upped their price target on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. HC Wainwright increased their price objective on shares of Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Guggenheim lifted their price objective on shares of Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.14.
View Our Latest Analysis on ROIV
Institutional Investors Weigh In On Roivant Sciences
Large investors have recently made changes to their positions in the company. Fifth Third Bancorp boosted its stake in Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock valued at $130,000 after buying an additional 376 shares during the last quarter. Bessemer Group Inc. increased its stake in Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its stake in Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock worth $282,000 after acquiring an additional 445 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Roivant Sciences by 13.9% during the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock worth $141,000 after acquiring an additional 487 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in shares of Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after acquiring an additional 500 shares in the last quarter. 64.76% of the stock is owned by institutional investors.
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.
Featured Articles
- Five stocks we like better than Roivant Sciences
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
